Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30482218 | 1.00 | BRPF1 (0.41) | BRPF1CREBBPTSHRGSK3BPOLB | |
| SCHEMBL15231700 | 0.76 | CREBBP (0.46) | BRPF1CREBBPTSHRGSK3BPOLB | |
| SCHEMBL30212561 | 0.76 | BRPF1 (0.46) | BRPF1CREBBPTSHRGSK3BPOLB | |
| SCHEMBL24156584 | 0.76 | BRPF1 (0.46) | BRPF1CREBBPTSHRGSK3BPOLB | |
| SCHEMBL25312184 | 0.70 | BRPF1 (0.42) | BRPF1CREBBPTSHRGSK3BPOLB | |
| SCHEMBL21624088 | 0.70 | MOGAT2 (0.33) | — | |
| SCHEMBL30511362 | 0.70 | BRPF1 (0.42) | BRPF1CREBBPTSHRGSK3BPOLB | |
| SCHEMBL25376593 | 0.70 | BRPF1 (0.42) | BRPF1CREBBPTSHRGSK3BPOLB | |
| SCHEMBL30482267 | 0.70 | BRPF1 (0.42) | BRPF1CREBBPTSHRGSK3BPOLB | |
| SCHEMBL29968384 | 0.70 | MOGAT2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098024-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4469449-A1 | PARP1 INHIBITORS AND USES THEREOF | Xinthera, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146957-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146957-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098024-A1 | PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP16 | BRPF1 1448/4885CREBBP 923/4885TSHR 2477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.